Ville Raymond Wallenius

List of Publications by Year
in descending order

61 papers	3,984 citations	201575 27 h-index	128225 60 g-index
62 all docs	62 docs citations	62 times ranked	5073 citing authors

#	Article	IF	Citations
1	Healthy Subcutaneous and Omental Adipose Tissue Is Associated with High Expression of Extracellular Matrix Components. International Journal of Molecular Sciences, 2022, 23, 520.	1.8	16
2	Comparing effects of obesity treatment with very low energy diet and bariatric surgery after 2 years: a prospective cohort study. BMJ Open, 2022, 12, e053242.	0.8	3
3	The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Science Advances, 2022, 8, eabm7012.	4.7	13
4	A Fatty Diet Induces a Jejunal Ketogenesis Which Inhibits Local SGLT1-Based Glucose Transport via an Acetylation Mechanismâ€"Results from a Randomized Cross-Over Study between Iso-Caloric High-Fat versus High-Carbohydrate Diets in Healthy Volunteers. Nutrients, 2022, 14, 1961.	1.7	3
5	Lipoxins reduce obesity-induced adipose tissue inflammation in 3D-cultured human adipocytes and explant cultures. IScience, 2022, 25, 104602.	1.9	4
6	Laparoscopic Heller myotomy or pneumatic dilatation in achalasia: results of a prospective, randomized study with at least a decade of follow-up. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1618-1625.	1.3	8
7	Intestinal sodium/glucose cotransporter 3 expression is epithelial and downregulated in obesity. Life Sciences, 2021, 267, 118974.	2.0	9
8	The BAriatic surgery SUbstitution and nutrition (BASUN) population: a data-driven exploration of predictors for obesity. BMC Endocrine Disorders, 2021, 21, 183.	0.9	2
9	Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Dietsâ€"Data from a Randomized Cross-Over Study in Healthy Subjects. Nutrients, 2021, 13, 3322.	1.7	3
10	Impact of obesity on intensive care outcomes in patients with COVID-19 in Swedenâ€"A cohort study. PLoS ONE, 2021, 16, e0257891.	1.1	33
11	Potential Benefits and Harms of Gastric Bypass Surgery in Obese Individuals With Type 1 Diabetes: A Nationwide, Matched, Observational Cohort Study. Diabetes Care, 2020, 43, 3079-3085.	4.3	17
12	Glycocholic acid and butyrate synergistically increase vitamin D-induced calcium uptake in Caco-2 intestinal epithelial cell monolayers. Bone Reports, 2020, 13, 100294.	0.2	6
13	Suppression of enteroendocrine cell glucagon-like peptide (GLP)-1 release by fat-induced small intestinal ketogenesis: a mechanism targeted by Roux-en-Y gastric bypass surgery but not by preoperative very-low-calorie diet. Gut, 2020, 69, 1423-1431.	6.1	19
14	Fucose-Galactose Polymers Inhibit Cholera Toxin Binding to Fucosylated Structures and Galactose-Dependent Intoxication of Human Enteroids. ACS Infectious Diseases, 2020, 6, 1192-1203.	1.8	11
15	Sleeve gastrectomy and Roux-en-Y gastric bypass in the treatment of type 2 diabetes. Two-year results from a Swedish multicenter randomized controlled trial. Surgery for Obesity and Related Diseases, 2020, 16, 1035-1044.	1.0	23
16	Design and baseline data in the BAriatic surgery SUbstitution and Nutrition study (BASUN): a 10-year prospective cohort study. BMC Endocrine Disorders, 2020, 20, 23.	0.9	11
17	Rates and types of injuries during the three consecutive years 2016 to 2018 of the VÃtternrundanâ€"One of the worldâ€™s largest and longest bicycle races. Traffic Injury Prevention, 2019, 20, 749-752.	0.6	1
18	Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. Scientific Reports, 2019, 9, 15385.	1.6	19

#	Article	IF	Citations
19	The gut microbiota is a major regulator of androgen metabolism in intestinal contents. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1182-E1192.	1.8	118
20	Proteomic Approach to the Potential Role of Angiotensin II in Barrett Dysplasia. Proteomics - Clinical Applications, 2019, 13, 1800102.	0.8	6
21	Fucosylated Molecules Competitively Interfere with Cholera Toxin Binding to Host Cells. ACS Infectious Diseases, 2018, 4, 758-770.	1.8	42
22	Glycemic Control after Sleeve Gastrectomy and Roux-En-Y Gastric Bypass in Obese Subjects with Type 2 Diabetes Mellitus. Obesity Surgery, 2018, 28, 1461-1472.	1.1	40
23	Obesity-induced changes in lipid mediators persist after weight loss. International Journal of Obesity, 2018, 42, 728-736.	1.6	33
24	Biliopancreatic Diversion is associated with greater increases in energy expenditure than Roux-en-Y Gastric Bypass. PLoS ONE, 2018, 13, e0194538.	1.1	10
25	GM1 ganglioside-independent intoxication by Cholera toxin. PLoS Pathogens, 2018, 14, e1006862.	2.1	57
26	Intestinal Sodium Glucose Transporter 3 (SGLT3) is Downregulated in Experimental Models of Obesity and in Morbidly Obese Patients. FASEB Journal, 2018, 32, 670.46.	0.2	0
27	AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia, 2017, 60, 729-739.	2.9	20
28	Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched caseâ€“control study with 2 years of follow-up. International Journal of Obesity, 2017, 41, 210-216.	1.6	45
29	Roux-en-Y Gastric Bypass Surgery Increases Respiratory Quotient and Energy Expenditure during Food Intake. PLoS ONE, 2015, 10, e0129784.	1.1	30
30	Local expression of AP/AngIV/IRAP and effect of AngIV on glucose-induced epithelial transport in human jejunal mucosa. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1101-1108.	1.0	2
31	Surgery in the treatment of type 2 diabetes mellitus. Scandinavian Journal of Surgery, 2015, 104, 40-47.	1.3	34
32	Angiotensin II exerts dual actions on sodium-glucose transporter 1-mediated transport in the human jejunal mucosa. Scandinavian Journal of Gastroenterology, 2015, 50, 1068-1075.	0.6	9
33	Expression of tight-junction proteins in human proximal small intestinal mucosa before and after Roux-en-Y gastric bypass surgery. Surgery for Obesity and Related Diseases, 2015, 11, 45-53.	1.0	45
34	Bone mineral density and expression of vitamin D receptor-dependent calcium uptake mechanisms in the proximal small intestine after bariatric surgery. British Journal of Surgery, 2014, 101, 1566-1575.	0.1	25
35	Interleukinâ€6 mediates exerciseâ€induced increase in insulin sensitivity in mice. Experimental Physiology, 2012, 97, 1224-1235.	0.9	41
36	Gastric Bypass Surgery Is Followed by Lowered Blood Pressure and Increased Diuresis - Long Term Results from the Swedish Obese Subjects (SOS) Study. PLoS ONE, 2012, 7, e49696.	1.1	87

#	Article	IF	Citations
37	Central Nervous System Lipocalin-Type Prostaglandin D2-Synthase is Correlated with Orexigenic Neuropeptides, Visceral Adiposity and Markers of the Hypothalamic-Pituitary-Adrenal Axis in Obese Humans. Journal of Neuroendocrinology, 2011, 23, 501-507.	1.2	10
38	The Lipocalins Retinol-Binding Protein-4, Lipocalin-2 and Lipocalin-Type Prostaglandin D2-Synthase Correlate with Markers of Inflammatory Activity, Alcohol Intake and Blood Lipids, But not with Insulin Sensitivity in Metabolically Healthy 58-year-Old Swedish Men. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 75-80.	0.6	32
39	Erythrocyte sodium-lithium countertransport activity is inversely correlated to adiponectin, retinol binding protein 4 and body height. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 487-491.	0.6	0
40	Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. Journal of Applied Physiology, 2007, 102, 820-823.	1.2	30
41	Increased Levels of Acylation-Stimulating Protein in Interleukin-6-Deficient (IL-6â^'/â^') Mice. Endocrinology, 2006, 147, 2690-2695.	1.4	23
42	Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R551-R557.	0.9	81
43	Mature-Onset Obesity in Interleukin-1 Receptor I Knockout Mice. Diabetes, 2006, 55, 1205-1213.	0.3	153
44	Interleukin-1 System Gene Polymorphisms Are Associated with Fat Mass in Young Men. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2749-2754.	1.8	47
45	Lack of Complement Factor C3, but Not Factor B, Increases Hyperlipidemia and Atherosclerosis in Apolipoprotein Eâ^'/â^' Low-Density Lipoprotein Receptorâ^'/â^' Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1062-1067.	1.1	90
46	Up-regulation of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis factor-alpha and interleukin-6 in liver parenchymal cells. Journal of Hepatology, 2004, 41, 538-544.	1.8	26
47	On the site and mechanism of action of the anti-obesity effects of interleukin-6. Growth Hormone and IGF Research, 2003, 13, S28-S32.	0.5	31
48	The therapeutic potential of interleukin-6 in treating obesity. Expert Opinion on Biological Therapy, 2003, 3, 1061-1070.	1.4	32
49	Interleukin-6 Levels in the Central Nervous System Are Negatively Correlated with Fat Mass in Overweight/Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4379-4383.	1.8	124
50	Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochemical and Biophysical Research Communications, 2002, 293, 560-565.	1.0	207
51	Interleukin-6-deficient mice develop mature-onset obesity. Nature Medicine, 2002, 8, 75-79.	15.2	1,073
52	Retarded Liver Growth in Interleukin-6-Deficient and Tumor Necrosis Factor Receptor-1-Deficient Mice*. Endocrinology, 2001, 142, 2953-2960.	1.4	19
53	Liver-Derived IGF-I Regulates GH Secretion at the Pituitary Level in Mice. Endocrinology, 2001, 142, 4762-4770.	1.4	74
54	Overexpression of the Hepatocyte Growth Factor (HGF) Receptor (Met) and Presence of a Truncated and Activated Intracellular HGF Receptor Fragment in Locally Aggressive/Malignant Human Musculoskeletal Tumors. American Journal of Pathology, 2000, 156, 821-829.	1.9	72

#	Article	IF	Citations
55	Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL-6â^'/â^') mice. Journal of Hepatology, 2000, 33, 967-974.	1.8	26
56	Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7088-7092.	3.3	826
57	Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas. Oncogene, 1999, 18, 3226-3234.	2.6	23
58	Hepatocyte-stimulated expression of hepatocyte growth factor (HGF) in cultured rat hepatic stellate cells. Journal of Hepatology, 1999, 30, 115-124.	1.8	40
59	Insulin-Like Growth Factors Stimulate Expression of Hepatocyte Growth Factor But Not Transforming Growth Factor Î²1 in Cultured Hepatic Stellate Cells*. Endocrinology, 1997, 138, 4683-4689.	1.4	54
60	Changes in expression of CCAAT/enhancer binding protein Î± (C/EBPÎ±) and C/EBPÎ² in rat liver after partial hepatectomy but not after treatment with cyproterone acetate. Journal of Hepatology, 1997, 27, 903-911.	1.8	22
61	Chromosomal localization of rat hepatocyte growth factor (Hgf) and HGF receptor (Met) and characterization of HGF receptor cDNA. Mammalian Genome, 1997, 8, 661-667.	1.0	20